NYMXF — Nymox Pharmaceutical Cashflow Statement
0.000.00%
Last trade - 00:00
- $19.58m
- $19.51m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -10.6 | -13.2 | -11.7 | -12.5 | -6.58 |
Depreciation | |||||
Non-Cash Items | 3.92 | 4.9 | 2.01 | 2.85 | 0.864 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.13 | 0.826 | -0.314 | -0.14 | 0.495 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -7.8 | -7.43 | -10 | -9.82 | -5.21 |
Capital Expenditures | -0.036 | 0 | -0.013 | -0.006 | 0 |
Purchase of Fixed Assets | |||||
Cash from Investing Activities | -0.036 | 0 | -0.013 | -0.006 | 0 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 14.9 | 4.72 | 8.42 | 7.04 | 5.78 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 7.09 | -2.71 | -1.63 | -2.78 | 0.573 |